TPX-200 is, like TPX-100, based on MEPE (matrix extracellular phosphoglycoprotein). TPX-200 is regarded as a phosphatonin molecule, with the potential broadly to benefit both bone strength and kidney function through its effects on phosphate metabolism. In non-clinical studies, OrthoTrophix has confirmed the following effects of TPX-200 in chronic kidney disease models and other models.
- Reduction of bone porosity in a chronic kidney disease model
- Inhibition of intestinal phosphate absorption
- Inhibition of renal phosphate re-absorption
- Reduction in circulating levels of PTH in a chronic kidney disease model
TPX-200 has potential to be the first therapeutic to address key conditions associated with chronic kidney disease: CKD-MBD (formerly known as renal osteodystrophy), hyperphosphatemia, and hyperparathyroidism.